Date: 2017-05-03
Type of information: Opening of new premises
Compound: CAR T-cell manufacturing facility in Shanghai
Company: CARsgen Therapeutics (China)
Therapeutic area: Cancer - Oncology - Technology - Services
Type agreement: opening of new premises
Action mechanism:
Disease:
Details:
- • On May 3, 2017, CARsgen Therapeutics, a chinese company developing chimeric antigen receptor T-cell (CAR-T cell) therapies for solid tumors, has announced the opening of its new manufacturing facility in Shanghai. The facility features state-of-art capabilities to manufacture vectors and CAR-T cells to support CARsgen clinical programs. Upon completion of its final inspections, the 33,000-square-foot facility is expected to become China's first CAR-T cell manufacturing platform that is in strict compliance with current good manufacturing procedure (cGMP) regulations of China Food and Drug Administration (CFDA).
- Founded in 2014, CARsgen Therapeutics completed B series of financing of $30M in early 2016. Two of its CAR-T cell therapies, anti-GPC3 CAR-T for hepatocellular carcinoma and anti-EGFR CAR-T for glioblastoma multiforme have entered clinical trials. The company also plans to submit about 5 Investigational New Drug (IND) applications to CFDA and get at least one IND approval from the FDA by the end of 2018.
Financial terms:
Latest news:
Is general: Yes
